Regeneron Pharmaceuticals Grants 10‑Year Performance Awards to CEO & CSO

What Happened

• Regeneron Pharmaceuticals announced on Sept. 24, 2026 that its Compensation Committee granted one‑time Performance Share Unit awards ("2026 PSUs") to co‑chairs and co‑founders Leonard S. Schleifer, M.D., Ph.D. (CEO) and George D. Yancopoulos, M.D., Ph.D. (CSO).
• The awards are 100% performance‑based, span a 10‑year performance period ending Dec. 31, 2035, and replace the executives' annual long‑term incentive awards through 2036. Delivered shares are subject to a mandatory holding period that generally prevents sale until Feb. 2036 (with narrow exceptions for death, disability, or change in control).

Key Details

• Grant date: Sept. 24, 2026; awards governed by Regeneron's 2014 Long‑Term Incentive Plan and PSU agreements (Exhibits 10.1, 10.2).
• Payout structure: largest earnout tied to nearly $30 billion in new product annual revenues (about 2x Regeneron’s 2025 total revenue); below $10 billion in new product revenue, no revenue‑based PSUs are earned.
• Caps and allocations: hard caps of 2,700,000 PSUs for the CEO and 2,900,000 PSUs for the CSO; activity‑based earnout capped at 100,000 PSUs (CEO) and 300,000 PSUs (CSO) when revenue < $10B.
• Governance and adjustments: a relative TSR modifier versus the NASDAQ Biotechnology Total Return Index can adjust earned PSUs by ±20%; any shares delivered early are subject to a 20% holdback pending final TSR adjustment in 2036. Executives must generally remain in service through measurement dates or forfeit unvested PSUs; succession‑planning participation is required.

Why It Matters

• For investors, the awards tie the co‑founders' compensation tightly to long‑term pipeline success and significant new product revenue generation, concentrating upside on transformational commercial outcomes rather than short‑term metrics.
• The structure includes high performance hurdles, long lockups, and a relative TSR overlay — which aim to align executive pay with shareholder returns but also defer potential dilution and compensation expense into the long term.
• Separately, Regeneron formed a majority‑owned new subsidiary to explore a non‑core opportunity and granted each executive an equity stake; the subsidiary currently has nominal value, no significant assets, and has not commenced operations.